Update: PrescribeIT and TPP Type 1 Prescribing Requirements

Reposted for information: this update was originally provided in May 2023.

At their May 2023 meeting, the TPP Steering Committee (TPPSC) approved continued exemption from the use of TPP forms for TPP Type 1 drugs, for prescribers and pharmacies using PrescribeIT to prescribe, transmit and receive electronically-generated prescriptions. This interim approval is in place until Nov. 2, 2023, when the TPPSC next meets.

To meet TPP Alberta requirements, the TPPSC has asked PrescribeIT to work towards mandatory reporting of medical indication for Type 1 drugs. TPP will work with Canada Health Infoway towards solutions, and ongoing exemption will be dependent on progress towards this goal.

Under the conditional approval, prescribers and pharmacies enabled with PrescribeIT may continue using the system for TPP drug prescribing and do not need to use TPP prescription forms for Type 1 drugs. As communicated previously, the following conditions must be met to qualify for the exemption:

• Both the prescriber and pharmacy must be PrescribeIT-enabled and using PrescribeIT for system-to-system communications, and

• The patient has choice in the pharmacy at which their prescriptions are filled, i.e., patients must not be directed to only PrescribeIT-enabled pharmacies.